 SOUTH SAN FRANCISCO, Calif., May 13, 2021 GLOBE NEWSWIRE -- Vera Therapeutics, Inc. Vera, a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of 11.00 per share. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be 47.85 million. All of the shares are being offered by Vera. In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 652,500 shares of its Class A common stock at the initial public offering price, less the underwriting discounts and commissions. 